Nilotinib
Spezifikationen
641571-10-0CAS-Nummer
700-544-5EG-Nummer
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamideIUPAC-Name
C28H22F3N7OChemische Formel
529.5 g/molMolekulargewicht
Nilotinib; 641571-10-0; AMN 107; AMN-107; nilotinibum; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; Danziten; NSC-747599; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; DTXSID5042663; F41401512X; CHEBI:52172; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; RefChem:58968; AMN 107 Base; DTXCID3022663; L01XE08; benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate; Tasigna; AMN107; Nilotinib (AMN-107); Nilotinib free base; MFCD09833716; C28H22F3N7O; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEMBL255863; NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN]; Nilotinib [USAN:INN:BAN]; Nilotinib?; HSDB 7842; UNII-F41401512X; 641571-10-0 (free base); Nilotinib (Standard); 3gp0; NILOTINIB [INN]; NILOTINIB [MI]; Nilotinib (USAN/INN); NILOTINIB [HSDB]; 1353151-22-0; NILOTINIB [VANDF]; NILOTINIB [MART.]; EC 700-544-5; NILOTINIB [USP-RS]; NILOTINIB [WHO-DD]; SCHEMBL7901; NILOTINIB [EMA EPAR]; MLS003915611; MLS006010160; Nilotinib - Bio-X trade mark; GTPL5697; orb1224371; orb1308331; orb3141255; SCHEMBL29366964; SCHEMBL29580067; GLXC-90226; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; HMS5079M05; EX-A8380; TAC35617; AC-647; BDBM50237710; EBC-11364; HY-10159R; MSK159953; NSC800804; s1033; AKOS005063561; CCG-264784; CS-0102; DB04868; FM10831; NSC 747599; NSC-800804; SB17315; SDCCGSBI-0634418.P004; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-12; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzamide; AS-16214; BN164654; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; SY024415; N3346; NS00000665; SW218083-2; T1524; D08953; N-8207; AB01273978-01; AB01273978-02; AB01273978_03; EN300-7381984; F079266; Q412327; SR-01000931150; SR-01000931150-2; BRD-K81528515-001-04-7; BRD-K81528515-001-13-8; Z1741976994; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)Synonyme
Produkte, die Nilotinib enthalten
NILOTINIB ACCORD 50 MG CAPSULAS DURAS EFGNILOTINIB ACCORD 200 MG CAPSULAS DURAS EFGNILOTINIB ACCORD 150 MG CAPSULAS DURAS EFGTASIGNA 200 MG CAPSULAS DURASTASIGNA 150 MG CAPSULAS DURASNILOTINIB ZENTIVA 200 MG CAPSULAS DURAS EFGNILOTINIB ZENTIVA 150 MG CAPSULAS DURAS EFGNILOTINIB ZENTIVA 200 mg, géluleNILOTINIB ZENTIVA 150 mg, géluleNILOTINIB ACCORD 200 mg, géluleNILOTINIB ACCORD 150 mg, géluleTasigna 200mg
Seite 1 von 3
Unternehmen, die Nilotinib verkaufen
SL
Suzhou Lixin Pharmaceutical Co., LtdChinaSI
Sinoway Industrial Co.Ltd.ChinaSQ
SICHUAN QINGMU PHARMACEUTICAL CO.,LTD.ChinaSX
Sichuan Xieli Pharmaceutical Co., Ltd.ChinaAH
Accord Healthcare S.L.U.SpainNE
Novartis Europharm LimitedSpainSeite 1 von 2